Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 10/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13178850 | 0.93 | CASP1 (0.35) | XIAPCYP3A4 | |
| SCHEMBL10201744 | 0.81 | XIAP (0.35) | CCKBRXIAPCYP3A4 | |
| SCHEMBL10201727 | 0.79 | XIAP (0.40) | CCKBRXIAPCYP3A4 | |
| SCHEMBL10268242 | 0.79 | XIAP (0.37) | XIAPCYP3A4 | |
| SCHEMBL10201746 | 0.77 | CASP1 (0.43) | XIAPCYP3A4 | |
| SCHEMBL10201747 | 0.77 | CASP1 (0.43) | XIAPCYP3A4 | |
| SCHEMBL10249440 | 0.74 | CASP1 (0.36) | CCKBRXIAPCYP3A4 | |
| SCHEMBL10201739 | 0.74 | CASP1 (0.36) | CCKBRXIAPCYP3A4 | |
| SCHEMBL10201335 | 0.67 | CASP1 (0.52) | XIAPCYP3A4 | |
| SCHEMBL644733 | 0.67 | CASP1 (0.50) | XIAPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CCKBR 3516/4885XIAP 257/4885CYP3A4 2587/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CCKBR 3516/4885XIAP 257/4885CYP3A4 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.